Xin Lang Cai Jing·2025-07-29 02:58Group 1 - The innovation drug ETF (560900) has seen a rise of 2.64% with a trading volume of 14.26 million yuan, indicating active market participation [1] - The CSI Innovation Drug Industry Index (931152) increased by 2.86%, with notable gains from stocks such as Jiuzhou Pharmaceutical (603456) up 9.17%, Tigermed (300347) up 8.60%, and WuXi AppTec (603259) up 6.70% [1] - As of July 28, the latest scale of the innovation drug ETF reached 61.85 million yuan, with a total of 62.97 million shares, both marking a six-month high [1] Group 2 - The National Healthcare Security Administration announced that the 11th batch of centralized procurement will optimize specific rules, moving away from solely relying on the lowest bid, which is expected to alleviate excessive competition in the pharmaceutical industry [2] - Domestic CRO and CDMO sectors are benefiting from the global recovery of innovative drugs, with leading companies like WuXi AppTec and WuXi Biologics reporting strong mid-year performance [2] - The CSI Innovation Drug Industry Index reflects the overall performance of up to 50 representative listed companies involved in innovative drug research and development [2]